Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewDD 03-171 is a potent and selective BTK Degrader (PROTAC®) (DC50 = 5.1 nM); degrades BTK in a proteasome- and CRBN-dependent manner. Suppresses BTK signaling and proliferation in mantle cell lymphoma (MCL) cells by degrading BTK, IKFZ1, and IKFZ3 (3 validated targets in B-cell malignancies). Also degrades Ibrutinib (Cat. No. 6813) -resistant C481S-BTK mutant cancer cells. Exhibits no binding against a panel of 468 kinases at 1 μM. Reduces tumor burden and extends survival in lymphoma patient-derived xenograft models.
BTK antibodies validated for Western Blot also available: Catalog # MAB5807 and NBP2-02472.
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Sold under license from Dana-Farber Cancer Institute
M. Wt | 991.16 |
Formula | C55H62N10O8 |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
CAS Number | 2366132-45-6 |
PubChem ID | 138059681 |
InChI Key | QBPVFCNYKUENHU-UHFFFAOYSA-N |
Smiles | CN1C=C(N=C(NC2=CC=C(C=C2)C(=O)N2CCN(CCCCCCNC(=O)CNC3=C4C(=O)N(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)CC2)C1=O)C1=C(C)C(NC(=O)C2=CC=C(C=C2)C(C)(C)C)=CC=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 49.56 | 50 |
The following data is based on the product molecular weight 991.16. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.5 mM | 2.02 mL | 10.09 mL | 20.18 mL |
2.5 mM | 0.4 mL | 2.02 mL | 4.04 mL |
5 mM | 0.2 mL | 1.01 mL | 2.02 mL |
25 mM | 0.04 mL | 0.2 mL | 0.4 mL |
References are publications that support the biological activity of the product.
Dobrovolsky et al (2019) Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. Blood 133 952 PMID: 30545835
If you know of a relevant reference for DD 03-171, please let us know.
Keywords: DD 03-171, DD 03-171 supplier, DD03-171, Potent, selective, BTK, active, degraders, degrades, IKFZ1, IKFZ3, C481S-BTK, B-cell, malignancies, Bruton, tyrosine, kinase, PROTAC, PROTACs, targeted, protein, degradation, tpd, Brutons, Tyrosine, Kinase, (BTK), Degraders, 7160, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for DD 03-171. Do you know of a great paper that uses DD 03-171 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review DD 03-171 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This brochure highlights the tools and services available from Bio-Techne to support your Targeted Protein Degradation and Induced Proximity research, including:
Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia